RSAR: Post-marketing RX Drug Abuse Surveillance Data - IBH (Data Source)

The Food and Drug Administration is forecasting a contractual opportunity to acquire post-marketing prescription drug abuse surveillance data through an independent behavioral health entity, targeted for fiscal year 2026. This initiative aims to support ongoing monitoring of prescription drug misuse and abuse patterns following market approval, leveraging real-world data to enhance public health surveillance and regulatory decision-making. The contractor will be expected to collect, anonymize, analyze, and report timely and accurate data on prescription drug utilization trends, diversion indicators, and associated health outcomes to inform FDA’s risk evaluation and mitigation strategies. The procurement falls under the NAICS code 541990, classifying it as other scientific and technical consulting services, indicating the need for specialized expertise in pharmacovigilance, data analytics, and behavioral health research. While the solicitation number and specific set-aside status are not yet defined, the opportunity is open to qualified vendors capable of delivering robust, scalable surveillance systems. Performance is expected to occur without designated geographic restrictions, and all inquiries should be directed to the CDER Acquisition Liaison at cderacquisitions@fda.hhs.gov, with the Contracting Officer role to be assigned at a later date. The forecast was published on May 25, 2026, and interested parties can access further details via the designated online portal.